Potentials of ribosomopathy gene as pharmaceutical targets for cancer treatment

Wang, Mengxin; Vulcano, Stephen; Xu, Changlu; Xie, Renjian; Peng, Weijie; Wang, Jie; Liu, Qiaojun; Jia, Lee; Li, Zhi; Li, Yumei

doi:10.1016/j.jpha.2023.10.001

Cited by 2 publications

(1 citation statement)

References 166 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For cancer therapy, the drug must reach the cancer cell at desired dosage, while other adjacent normal cells should be intact. Indeed, targeted cancer therapy would be of great importance for scientists to develop drug delivery systems with high efficacy (3,4). Recently, bio-compatible magnetic nanocarriers have attracted much attention due to their superior properties in cancer treatment (5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

Theoretical investigations on modeling blood flow through vessel for understanding effectiveness of magnetic nanocarrier drug delivery systems

Alzhrani,

Aldawsari,

Alamoudi

2024

Front. Med.

View full text Add to dashboard Cite

For cancer therapy, the focus is now on targeting the chemotherapy drugs to cancer cells without damaging other normal cells. The new materials based on bio-compatible magnetic carriers would be useful for targeted cancer therapy, however understanding their effectiveness should be done. This paper presents a comprehensive analysis of a dataset containing variables x(m), y(m), and U(m/s), where U represents velocity of blood through vessel containing ferrofluid. The effect of external magnetic field on the fluid flow is investigated using a hybrid modeling. The primary aim of this research endeavor was to construct precise and dependable predictive models for velocity, utilizing the provided input variables. Several base models, including K-nearest neighbors (KNN), decision tree (DT), and multilayer perceptron (MLP), were trained and evaluated. Additionally, an ensemble model called AdaBoost was implemented to further enhance the predictive performance. The hyper-parameter optimization technique, specifically the BAT optimization algorithm, was employed to fine-tune the models. The results obtained from the experiments demonstrated the effectiveness of the proposed approach. The combination of the AdaBoost algorithm and the decision tree model yielded a highly impressive score of 0.99783 in terms of R2, indicating a strong predictive performance. Additionally, the model exhibited a low error rate, as evidenced by the root mean square error (RMSE) of 5.2893 × 10−3. Similarly, the AdaBoost-KNN model exhibited a high score of 0.98524 using R2 metric, with an RMSE of 1.3291 × 10−2. Furthermore, the AdaBoost-MLP model obtained a satisfactory R2 score of 0.99603, accompanied by an RMSE of 7.1369 × 10−3.

show abstract

Section: Introductionmentioning

confidence: 99%

Theoretical investigations on modeling blood flow through vessel for understanding effectiveness of magnetic nanocarrier drug delivery systems

Alzhrani,

Aldawsari,

Alamoudi

2024

Front. Med.

View full text Add to dashboard Cite

show abstract

Multiple myeloma: clinical characteristics, current therapies and emerging innovative treatments targeting ribosome biogenesis dynamics

Elbahoty,

Papineni,

Samant

2024

Clin Exp Metastasis

View full text Add to dashboard Cite

Multiple myeloma (MM) is a clinical disorder characterized by aberrant plasma cell growth in the bone marrow microenvironment. Globally, the prevalence of MM has been steadily increasing at an alarming rate. In the United States, more than 30,000 cases will be diagnosed in 2024 and it accounts for about 2% of cancer diagnoses and more than 2% of cancer deaths, more than double the worldwide figure. Both symptomatic and active MM are distinguished by uncontrolled plasma cell growth, which results in severe renal impairment, anemia, hypercalcemia, and bone loss. Multiple drugs have been approved by the FDA and are now widely used in clinical practice for MM. Although triplet and quadruplet induction regimens, autologous stem cell transplantation (ASCT), and maintenance treatment are used, MM continues to be an incurable illness characterized by relapses that may occur at various phases of its progression. MM patients with frailty, extramedullary disease, plasma cell leukemia, central nervous system recurrence, functional high risk, and the elderly are among those with the greatest current unmet needs. The high cost of care is an additional challenge. MM cells are highly protein secretary cells and thus are dependent on the activation of certain translation pathways. MM also has a high chance of altering ribosomal protein-encoding genes like MYC mutation. In this article we discuss the importance of ribosome biogenesis in promoting MM and RNA polymerase I inhibition as an upcoming treatment with potential promise for MM patients. Graphical abstract

show abstract

Potentials of ribosomopathy gene as pharmaceutical targets for cancer treatment

Cited by 2 publications

References 166 publications

Theoretical investigations on modeling blood flow through vessel for understanding effectiveness of magnetic nanocarrier drug delivery systems

Theoretical investigations on modeling blood flow through vessel for understanding effectiveness of magnetic nanocarrier drug delivery systems

Multiple myeloma: clinical characteristics, current therapies and emerging innovative treatments targeting ribosome biogenesis dynamics

Contact Info

Product

Resources

About